Physician profile
Brandy Franklin
NPI 1558084020
$1,431.13
in general payments reported to CMS, 2019-2025
19 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $496 · 2024: $638 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.55 | 2023-2025 | |
| Corium, LLC | $250.09 | 2023-2024 | Azstarys |
| Almatica Pharma LLC | $117.27 | 2023-2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $106.91 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $95.61 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.25 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $85.59 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $52.39 | 2024 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $43.59 | 2024 | |
| Vanda Pharmaceuticals INC. | $32.87 | 2024 | Hetlioz, Fanapt |
| Alkermes, INC. | $32.77 | 2023-2024 | Lybalvi, Aristada |
| Merck Sharp & Dohme LLC | $32.05 | 2024-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $28.12 | 2024 | |
| Collegium Pharmaceutical, INC. | $27.33 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $17.59 | 2024 | Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $16.76 | 2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $16.04 | 2025 | Cobenfy |
| Neuronetics, INC. | $13.82 | 2023 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $13.53 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.